Marjan Karegar, MD
Internal Medicine · Helena, ALNPI 1669621884
Payments from drug & device makers
Across 751 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$943
- Insulet Corporation$942
- Xeris Pharmaceuticals, Inc.$851
- Dexcom, Inc.$833
- Sanofi-aventis U.S. LLC$743
- plus $8K from 50 others
What the payments were for
- Food & beverage$14,04499%
- Education$560%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$197
- Minimed 670G System$136
- FARXIGA$125
- NATPARA (PARATHYROID HORMONE)$125
How this compares
$14,159 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 375 | $409,766 |
| OzempicSemaglutide | 156 | $216,788 |
| JardianceEmpagliflozin | 138 | $147,297 |
| TrulicityDulaglutide | 79 | $108,540 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 70 | $64,994 |
| Humulin R U-500Insulin Regular, Human | 37 | $61,621 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $50,508 |
| JanuviaSitagliptin Phosphate | 48 | $47,592 |
| FarxigaDapagliflozin Propanediol | 52 | $43,101 |
| Humalog Kwikpen U-100Insulin Lispro | 163 | $41,435 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $35,572 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $35,138 |
| Humalog Kwikpen U-200Insulin Lispro | 19 | $29,449 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $28,282 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 160 | $25,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,946 | $532,375513 claims |
| Novo NordiskOzempic, Novolog | $943 | $226,194184 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $524 | $193,299180 claims |
| MerckJanuvia, Janumet Xr | $74 | $67,04069 claims |
| AstraZenecaFarxiga | $443 | $43,10152 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $363 | $16,680995 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $743 | $14,59313 claims |
| AbbVieSynthroid | $422 | $12,140145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Helena
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.